POS0479 STAT3 DEGRADERS PROTECT FROM IMMUNOFIBROTIC CHANGES IN PRECLINICAL MODELS
P. Blyszczuk(Charles University), Oliver Distler(University Hospital of Zurich), Jared Gollob(Université Paris-Sud), Michele Mayo(Woomera Therapeutics), Nello Mainolfi(Akebia Therapeutics (United States)), C. Hubeau(Woomera Therapeutics), V. Tela(University of Zurich), Filip Rolski(Postgraduate School of Molecular Medicine), Gabriela Kania(University Hospital of Zurich), Anthony Slavin(Woomera Therapeutics), Vaishali Dixit(Woomera Therapeutics), Elena Pachera(University of Zurich), B. Yang(Woomera Therapeutics), Amela Hukara(University of Zurich)
Cited by 0
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
|New England Journal of Medicine|2013|961
Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
|The Journal of Heart and Lung Transplantation|2020|207
Complexity of TNF-α Signaling in Heart Disease
|Journal of Clinical Medicine|2020|171